Simtuzumab: Phase II data

A double-blind, U.S. and Russian Phase II trial in 236 patients with previously untreated advanced pancreatic cancer showed that 200 and 700 mg IV simtuzumab every 2 weeks plus Gemzar gemcitabine each missed the primary endpoint of improving median PFS vs. placebo plus Gemzar (3.5 and 3.7 months, respectively, vs. 3.7 months). There was no difference in adverse events between treatment groups. Data will be presented at the European Society for Medical Oncology meeting in Madrid this month. ...